Prenetics' IM8 revenue jumps 288% as cash flow turns positive

Prenetics reported Q2 revenue of $46.5 million, up 288 percent from a year earlier, as its IM8 supplement brand drove a sixth straight record quarter.

"Twenty months ago, IM8 did not exist. This quarter it carried Prenetics to a sixth consecutive record, July became the biggest month in our history, and consolidated Adjusted Free Cash Flow turned positive for the first time," Danny Yeung, chief executive officer of Prenetics and co-founder of IM8, said.

IM8 revenue reached $45.0 million, up 359 percent year over year, within the company's guidance of $44-46 million. July was the strongest month on record for the brand at $20.9 million, an annualized run-rate of $251 million. The company raised full-year total revenue guidance to $220-230 million and initiated FY2027 IM8 revenue guidance of $400 million or more, with nothing from upcoming product launches assumed. Earnings per share were not disclosed.

The Hong Kong-based company, whose IM8 brand is co-founded by David Beckham, said the brand ships to 46 countries and delivers more than 200,000 servings daily. IM8 reached about $251 million in annualized run-rate revenue within 20 months of launch, which the company calls the fastest growth ever recorded for a premium supplement brand. Gross margin improved to 64 percent in Q1 2026, and blended gross profit to customer-acquisition cost across all cohorts stood at 1.44 times.

Prenetics is funding growth through a $1 billion non-dilutive facility from General Catalyst's Customer Value Fund, which covers up to 70 percent of monthly marketing spend with repayments tied to cohort revenue. The company also named Caroline Levy, a veteran Wall Street consumer analyst and Celsius Holdings board member, as an independent director effective Aug. 17. Prenetics has divested non-core businesses including ACT Genomics, Europa and Insighta to focus on its consumer health operations.

The guidance raise signals management expects growth to accelerate through the second half, with adjusted free cash flow expected to stay positive for Q3 and beyond. Shares carry a median analyst price target of $29.50, according to recent coverage from Benchmark and Lake Street. Investors will watch the Q2 earnings webcast at 8:30 a.m. Eastern time for updated segment margins and product-launch timing.

This article is for informational purposes only and does not constitute investment advice.